Vascular Sclerostin Expression and Wnt Signaling Outside Plaques

What the evidence says

Sclerostin is present in vascular tissue. It was first identified in the vasculature through proteomic analyses in 2011, and it is now recognised to be expressed in the aorta, particularly in vascular smooth muscle cells (VSMCs) associated with vascular calcification. In atherosclerotic plaques from patients undergoing carotid endarterectomy, sclerostin concentration was higher in the media than in the intima. The same was true for VSMCs compared with infiltrating macrophages. All of these claims come from reviews. No claim here reports sclerostin measured in vessels free of plaque or calcification, so the page cannot say how much is expressed there.

The mechanism is well described. Sclerostin binds LRP5/6, antagonizes Wnt ligands, and so inhibits canonical Wnt/β-catenin signalling. Wnt activity in turn contributes to the osteochondrogenic transition of VSMCs during calcification. Experimental studies indicate that Wnt activation promotes matrix remodeling and calcific transformation, partly through matrix metalloproteinases and osteogenic transcriptional programs. A systematic review states that upregulated Wnt components facilitate arterial remodeling and VSMC transition toward the osteoblastic lineage. Sclerostin sits on the inhibiting side of this pathway.

Experimental manipulation points the same way. In murine warfarin-induced calcification models, sclerostin upregulation attenuates calcification. In ApoE−/− mice, transgenic sclerostin overexpression reduces atherosclerotic progression and aortic aneurysms through Wnt/β-catenin inhibition. In primary human aortic smooth muscle cells, recombinant sclerostin suppresses phosphate-induced calcification, downregulates RUNX2, and restores α-SMA expression. The evidence is mostly animal and cell-culture work. The claims give no human interventional data and no effect sizes.

How sclerostin is regulated in vascular tissue is less settled. Hypoxia regulates sclerostin in a tissue- and cell-type-specific manner. The effect varies across models, and the claims note a lack of human-relevant data. Whether sclerostin expression in VSMCs mainly marks a transition to osteoblast-like cells, or mainly restrains it, is interpreted differently across the sources (see below).

Where the evidence splits

Sclerostin expression under calcifying conditions points in different directions. In human aortic smooth muscle cells exposed to high phosphate, endogenous sclerostin was downregulated while RUNX2 and BMP2 were upregulated. Another review states that local vascular sclerostin is upregulated under calcifying stress, especially in CKD-associated vascular calcification. The claims do not say what separates these findings, such as model, cell source, or CKD context. The split is unexplained by the sources on this page.

Two readings of vascular sclerostin expression also coexist. One review proposes that elevated circulating sclerostin in dialysis patients, with higher local expression at calcifying foci, may be a compensatory response that restrains pathological Wnt signalling. Another says sclerostin expression in VSMCs likely reflects their transition to osteoblast-like cells. Both are interpretive and associational. The claims do not include a study that tests one reading against the other.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

• How much sclerostin and Wnt activity is present in vascular tissue without plaque or calcification, in humans?
• Does the media-greater-than-intima sclerostin pattern hold in vascular beds other than carotid plaques?
• What explains the opposite expression changes under calcifying conditions: downregulation in phosphate-exposed human aortic smooth muscle cells versus upregulation in CKD-associated calcification?
• Do the anti-calcific effects seen in warfarin and transgenic mouse models and in primary cell culture appear in human vasculature?